James M. McKenney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James M. McKenney has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Domenic Sica
Virginia Commonwealth University, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA +1 804 672 2133, ext. 12; +1 804 672 3369
3 shared publicationsCorinne Hanotin
2 shared publicationsEdward Cahill
2 shared publicationsHarold E. Bays
2 shared publicationsMichael H. Davidson
Rush-Presbyterian–St. Luke’s Medical Center, Chicago, Illinois
2 shared publicationsMichael J. Koren
2 shared publications
Latest Publications
- Open Access
- 1 July 2021
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 15 (4) , 593-601
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial
- 1 July 2021
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 15 (4) , 593-601
Open AccessLipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial
- 1 March 2015
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 9 (2) , 170-186
Understanding PCSK9 and anti-PCSK9 therapies
- 1 March 2015
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 9 (2) , 170-186
Understanding PCSK9 and anti-PCSK9 therapies
- 1 January 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (1) , 7-20
Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review
Patients with dyslipidemia receive a cardiovascular benefit from lowering low-density lipoprotein cholesterol (LDL-C). Atorvastatin is currently one of the most effective approved medications for lowering LDL-C, and has been shown to significantly reduce cardiovascular risk in many patient groups. However, even with substantial lowering of LDL-C with atorvastatin, patients still have a residual risk for coronary heart disease. Elevated triglyceride levels and low high-density lipoprotein cholesterol (HDL-C) levels may contribute to this risk. Approved medications targeting these secondary lipid parameters include fibrates, omega-3 fatty acids, and niacin. Among these medications, niacin provides the optimal increase in HDL-C levels and has efficacy similar to the other medications in lowering triglyceride levels. However, there are challenges to adherence with niacin treatment. The most common challenge during niacin treatment is flushing, although it typically decreases with ongoing use and can be ameliorated by pretreatment with aspirin and counseling by the prescriber. A combination of atorvastatin and niacin may provide more complete normalization of the lipid profile and increased cardiovascular benefits. A literature review of the PubMed and Embase databases was conducted for clinical studies that reported on the lipid-modifying efficacy of the atorvastatin plus niacin combination. Identified studies involved patients at risk for coronary heart disease and patients with established coronary heart disease. Overall, the studies were small but indicated that atorvastatin in combination with niacin was efficacious in normalizing lipid parameters. Larger lipid studies as well as studies evaluating cardiovascular outcomes during atorvastatin plus niacin treatment are warranted.
- 1 January 2012
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 124 (1) , 7-20
Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review
Patients with dyslipidemia receive a cardiovascular benefit from lowering low-density lipoprotein cholesterol (LDL-C). Atorvastatin is currently one of the most effective approved medications for lowering LDL-C, and has been shown to significantly reduce cardiovascular risk in many patient groups. However, even with substantial lowering of LDL-C with atorvastatin, patients still have a residual risk for coronary heart disease. Elevated triglyceride levels and low high-density lipoprotein cholesterol (HDL-C) levels may contribute to this risk. Approved medications targeting these secondary lipid parameters include fibrates, omega-3 fatty acids, and niacin. Among these medications, niacin provides the optimal increase in HDL-C levels and has efficacy similar to the other medications in lowering triglyceride levels. However, there are challenges to adherence with niacin treatment. The most common challenge during niacin treatment is flushing, although it typically decreases with ongoing use and can be ameliorated by pretreatment with aspirin and counseling by the prescriber. A combination of atorvastatin and niacin may provide more complete normalization of the lipid profile and increased cardiovascular benefits. A literature review of the PubMed and Embase databases was conducted for clinical studies that reported on the lipid-modifying efficacy of the atorvastatin plus niacin combination. Identified studies involved patients at risk for coronary heart disease and patients with established coronary heart disease. Overall, the studies were small but indicated that atorvastatin in combination with niacin was efficacious in normalizing lipid parameters. Larger lipid studies as well as studies evaluating cardiovascular outcomes during atorvastatin plus niacin treatment are warranted.
- 1 March 2010
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 4 (2) , 105-112.e1
Safety of extended-release niacin/laropiprant in patients with dyslipidemia
- 1 March 2010
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 4 (2) , 105-112.e1
Safety of extended-release niacin/laropiprant in patients with dyslipidemia
- Open Access
- 28 May 2009
- Published by Springer Nature in Nutrition Journal
- Vol. 8 (1) , 22
Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose
To provide an initial evaluation of insulin sensitivity and secretion indices derived from a standard liquid meal tolerance test protocol in subjects with normal (NFG), impaired fasting glucose (IFG) or type 2 diabetes mellitus.
- 28 May 2009
- Published by Springer Nature in Nutrition Journal
- Vol. 8 (1) , 22
Open AccessIndices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose
To provide an initial evaluation of insulin sensitivity and secretion indices derived from a standard liquid meal tolerance test protocol in subjects with normal (NFG), impaired fasting glucose (IFG) or type 2 diabetes mellitus.
- 12 November 2008
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (17) , 2947-2953
Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults
Background: Patients with persistent hypertriglyceridemia while on statin therapy may require adjunctive lipid-lowering therapy to meet treatment goals. Objective: To assess the effect of concomitant administration of prescription ω-3-acid ethyl esters (P-OM3), triglyceride-lowering agents, on the steady-state pharmacokinetics of rosuvastatin. Methods: A randomized, open-label, repeated-dose, two-way crossover drug interaction study of two treatments – 4 g P-OM3 plus 40 mg rosuvastatin or 40 mg rosuvastatin alone administered daily for 14 days each under fasting conditions – was conducted in 48 non-smoking healthy adults. Main outcome measures: The primary determinants of drug interaction were the ln-transformed area under the plasma concentration versus time curve [AUCt(ss)] over the final (day 14) 24 h dosing interval and maximum measured steady-state plasma rosuvastatin concentration [Cmax(ss)] on day 14. Safety was assessed by clinical and laboratory testing and recording of adverse events. Results: AUCt(ss) and Cmax(ss) following daily administration of rosuvastatin with P-OM3 were similar to those following monotherapy with rosuvastatin. All adverse events recorded during the study were classified as mild and self-limited. Conclusions: Administration of P-OM3 with rosuvastatin did not affect the pharmacokinetics of rosuvastatin under steady-state conditions in healthy individuals.
- 12 November 2008
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (17) , 2947-2953
Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults
Background: Patients with persistent hypertriglyceridemia while on statin therapy may require adjunctive lipid-lowering therapy to meet treatment goals. Objective: To assess the effect of concomitant administration of prescription ω-3-acid ethyl esters (P-OM3), triglyceride-lowering agents, on the steady-state pharmacokinetics of rosuvastatin. Methods: A randomized, open-label, repeated-dose, two-way crossover drug interaction study of two treatments – 4 g P-OM3 plus 40 mg rosuvastatin or 40 mg rosuvastatin alone administered daily for 14 days each under fasting conditions – was conducted in 48 non-smoking healthy adults. Main outcome measures: The primary determinants of drug interaction were the ln-transformed area under the plasma concentration versus time curve [AUCt(ss)] over the final (day 14) 24 h dosing interval and maximum measured steady-state plasma rosuvastatin concentration [Cmax(ss)] on day 14. Safety was assessed by clinical and laboratory testing and recording of adverse events. Results: AUCt(ss) and Cmax(ss) following daily administration of rosuvastatin with P-OM3 were similar to those following monotherapy with rosuvastatin. All adverse events recorded during the study were classified as mild and self-limited. Conclusions: Administration of P-OM3 with rosuvastatin did not affect the pharmacokinetics of rosuvastatin under steady-state conditions in healthy individuals.
- 1 June 2007
- Published by Elsevier in Atherosclerosis
- Vol. 192 (2) , 432-437
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
- 1 June 2007
- Published by Elsevier in Atherosclerosis
- Vol. 192 (2) , 432-437
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
- 1 May 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (5) , 715-728
Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia
A prescription form of omega‐3 fatty acids has been approved by the United States Food and Drug Administration as an adjunct to diet for the treatment of very high triglyceride levels. The active ingredients of omega‐3 fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are responsible for the triglyceride lowering. The prescription product contains a total of 0.84 g of these two active ingredients in every 1‐g capsule of omega‐3 fatty acids. The total EPA and DHA dose recommended for triglyceride lowering is approximately 2–4 g/day Fish oil products containing EPA and DHA are available without a prescription, but the American Heart Association advises that therapy with EPA and DHA to lower very high triglyceride levels should be used only under a physician's care. In patients with triglyceride levels above 500 mg/dl, approximately 4 g/day of EPA and DHA reduces triglyceride levels 45% and very low‐density lipoprotein cholesterol levels by more than 50%. Low‐density lipoprotein cholesterol levels may increase depending on the baseline triglyceride level, but the net effect of EPA and DHA therapy is a reduction in non–high‐density lipoprotein cholesterol level. Alternatively, patients may receive one of the fibrates (gemfibrozil or fenofibrate) or niacin for triglyceride lowering if their triglyceride levels are higher than 500 mg/dl. In controlled trials, prescription omega‐3 fatty acids were well tolerated, with a low rate of both adverse events and treatment‐associated discontinuations. The availability of prescription omega‐3 fatty acids, which ensures consistent quality and purity, should prove to be valuable for the medical management of hypertriglyceridemia.
- 1 May 2007
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (5) , 715-728
Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia
A prescription form of omega‐3 fatty acids has been approved by the United States Food and Drug Administration as an adjunct to diet for the treatment of very high triglyceride levels. The active ingredients of omega‐3 fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are responsible for the triglyceride lowering. The prescription product contains a total of 0.84 g of these two active ingredients in every 1‐g capsule of omega‐3 fatty acids. The total EPA and DHA dose recommended for triglyceride lowering is approximately 2–4 g/day Fish oil products containing EPA and DHA are available without a prescription, but the American Heart Association advises that therapy with EPA and DHA to lower very high triglyceride levels should be used only under a physician's care. In patients with triglyceride levels above 500 mg/dl, approximately 4 g/day of EPA and DHA reduces triglyceride levels 45% and very low‐density lipoprotein cholesterol levels by more than 50%. Low‐density lipoprotein cholesterol levels may increase depending on the baseline triglyceride level, but the net effect of EPA and DHA therapy is a reduction in non–high‐density lipoprotein cholesterol level. Alternatively, patients may receive one of the fibrates (gemfibrozil or fenofibrate) or niacin for triglyceride lowering if their triglyceride levels are higher than 500 mg/dl. In controlled trials, prescription omega‐3 fatty acids were well tolerated, with a low rate of both adverse events and treatment‐associated discontinuations. The availability of prescription omega‐3 fatty acids, which ensures consistent quality and purity, should prove to be valuable for the medical management of hypertriglyceridemia.